DrugPatentWatch Database Preview
Horizon Pharma Company Profile
What is the competitive landscape for HORIZON PHARMA, and what generic alternatives to HORIZON PHARMA drugs are available?
HORIZON PHARMA has two approved drugs.
There are eighteen US patents protecting HORIZON PHARMA drugs.
There are one hundred patent family members on HORIZON PHARMA drugs in thirty-eight countries and eight supplementary protection certificates in seven countries.
Summary for Horizon Pharma
| International Patents: | 100 |
| US Patents: | 18 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
| Patent Litigation for Horizon Pharma: | See patent lawsuits for Horizon Pharma |
Drugs and US Patents for Horizon Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-001 | Apr 30, 2013 | RX | Yes | No | 9,173,851*PED | Start Trial | Y | Start Trial | |||
| Horizon Pharma Usa | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-002 | Jul 26, 2012 | AB | RX | Yes | No | 9,504,699 | Start Trial | Start Trial | |||
| Horizon Pharma Usa | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-002 | Jul 26, 2012 | AB | RX | Yes | No | 8,309,124 | Start Trial | Start Trial | |||
| Horizon Pharma Usa | RAYOS | prednisone | TABLET, DELAYED RELEASE;ORAL | 202020-003 | Jul 26, 2012 | AB | RX | Yes | Yes | 8,168,218 | Start Trial | Y | Start Trial | ||
| Horizon Pharma Usa | PROCYSBI | cysteamine bitartrate | CAPSULE, DELAYED RELEASE;ORAL | 203389-001 | Apr 30, 2013 | RX | Yes | No | 9,233,077*PED | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for HORIZON PHARMA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 1 mg, 2 mg, and 5 mg | ➤ Subscribe | 2012-11-26 |
International Patents for Horizon Pharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 101466385 | Start Trial |
| Hong Kong | 1218066 | Start Trial |
| Taiwan | I649100 | Start Trial |
| Japan | 2002539167 | Start Trial |
| Israel | 171494 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Horizon Pharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1919458 | 122014000023 | Germany | Start Trial | PRODUCT NAME: CYSTEAMIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/13/861 20130906 |
| 1919458 | C 2014 012 | Romania | Start Trial | PRODUCT NAME: CISTEAMINABITARTRAT; NATIONAL AUTHORISATION NUMBER: EU/1/13/861; DATE OF NATIONAL AUTHORISATION: 20130906; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/861; DATE OF FIRST AUTHORISATION IN EEA: 20130906 |
| 1919458 | CR 2014 00013 | Denmark | Start Trial | PRODUCT NAME: CYSTEAMIN, HERUNDER MERCAPTAMINBITARTRAT; REG. NO/DATE: EU/1/13/861 20130906 |
| 1919458 | 194 50001-2014 | Slovakia | Start Trial | PRODUCT NAME: MERKAPTAMIN; FIRST REGISTRATION: EU/1/13/861, 20130906 |
| 1919458 | 19/2014 | Austria | Start Trial | PRODUCT NAME: CYSTEAMIN; REGISTRATION NO/DATE: EU/1/13/861/001-002 20130910 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
